EUVIMEDEUVIMED entdecken
Open Access

Novel chalcone 2-thiopyrimidine conjugates as dual VEGFR-2/BRAF inhibitors: design, synthesis, in vitro cytotoxicity, and molecular docking study

Randa Atef Ibrahim Abdelaziz iD, Heba Abdelrasheed Allam iD, Ahmed Mahmoud El Kerdawy iD, Mahmoud Taha Abo-Elfadl iD, Safinaz El-Sayed Abbas iD, Iman Ahmed Youssef Ghannam iD

RSC Medicinal Chemistry · 2025 · 16 (12) · 6299-6318

DOI: 10.1039/d5md00787a ↗

Kurz gefasst

Fachartikel in der Zeitschrift RSC Medicinal Chemistry, 2025. Verfasst von Randa Atef Ibrahim Abdelaziz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program in Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University Kasr El-Aini Street, P.O. Box,11562 Cairo Egypt. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A chalcone-based thiopyrimidine (4c) has displayed a potent anticancer activity via VEGFR-2 and BRAF inhibition.

Autor:innen und Institutionen

  • Postgraduate Program in Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University Kasr El-Aini Street, P.O. Box,11562 Cairo Egypt.
  • Egyptian Patent Office, Academy of Scientific Research and Technology Cairo Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University Kasr El-Aini street, P.O. Box,11562 Cairo Egypt Heba.abdelkhalek@pharma.cu.edu.eg.
  • School of Health and Care Sciences, College of Health and Science, University of Lincoln, Joseph Banks Laboratories Green Lane Lincoln UK.
  • Cancer Biology and Genetics Laboratory, Centre of Excellence for Advanced Sciences, National Research Centre Dokki Cairo 12622 Egypt.
  • Biochemistry Department, Biotechnology Research Institute, National Research Centre Dokki Cairo Egypt.

ORCID-Profile: Randa Atef Ibrahim Abdelaziz, Heba Abdelrasheed Allam, Ahmed Mahmoud El Kerdawy, Mahmoud Taha Abo-Elfadl, Safinaz El-Sayed Abbas, Iman Ahmed Youssef Ghannam

Zitieren

APA

Abdelaziz, R. A. I., Allam, H. A., El Kerdawy, A. M., Abo-Elfadl, M. T., Abbas, S. E., & Ghannam, I. A. Y. (2025). Novel chalcone 2-thiopyrimidine conjugates as dual VEGFR-2/BRAF inhibitors: design, synthesis, in vitro cytotoxicity, and molecular docking study. RSC Medicinal Chemistry, 16(12), 6299-6318. https://doi.org/10.1039/d5md00787a

Vancouver

Abdelaziz RAI, Allam HA, El Kerdawy AM, Abo-Elfadl MT, Abbas SE, Ghannam IAY. Novel chalcone 2-thiopyrimidine conjugates as dual VEGFR-2/BRAF inhibitors: design, synthesis, in vitro cytotoxicity, and molecular docking study. RSC Medicinal Chemistry. 2025;16(12):6299-6318. doi:10.1039/d5md00787a

BibTeX
@article{Abdelaziz2025,
  author = {Abdelaziz, Randa Atef Ibrahim and Allam, Heba Abdelrasheed and El Kerdawy, Ahmed Mahmoud and Abo-Elfadl, Mahmoud Taha and Abbas, Safinaz El-Sayed and Ghannam, Iman Ahmed Youssef},
  title = {Novel chalcone 2-thiopyrimidine conjugates as dual VEGFR-2/BRAF inhibitors: design, synthesis, in vitro cytotoxicity, and molecular docking study},
  journal = {RSC Medicinal Chemistry},
  year = {2025},
  volume = {16},
  number = {12},
  pages = {6299--6318},
  doi = {10.1039/d5md00787a}
}
Kostenlos starten →